This inventor holds 2 USPTO granted patents. Top assignees: Novartis Ag, Universitéde Strasbourg. Active years: 2010-2011.
Company Filing History:
2 out of 3,973 
2 out of 186 
Years Active: 2010-2011
Title: Thierry Léveillard: Innovator in Retinal Health
Introduction
Thierry Léveillard is a prominent inventor based in Maisons Alfort, France. He has made significant contributions to the field of retinal health through his innovative research and patented inventions. With a total of 2 patents, Léveillard's work focuses on the diagnosis and treatment of various retinal dystrophies.
Latest Patents
Léveillard's latest patents include groundbreaking methods and compositions for the early diagnosis, monitoring, and treatment of retinal conditions. One of his notable inventions is related to polynucleotides encoding rod-derived cone viability factor (RDCVF). This invention provides methods for diagnosing conditions such as age-related macular degeneration and Bardet-Biedl syndrome. It specifically highlights a protein, termed 'Rdcvf1,' which is differentially expressed in individuals suffering from retinal dystrophies compared to non-sufferers. His second patent focuses on enhancing cone cell survival through RDCVF, further contributing to the understanding and treatment of retinal diseases.
Career Highlights
Throughout his career, Léveillard has worked with esteemed organizations, including Novartis AG and Université de Strasbourg. His research has been pivotal in advancing the understanding of retinal health and developing therapeutic strategies for various retinal disorders.
Collaborations
Léveillard has collaborated with notable professionals in the field, including David Hicks and Jose-Alain Sahel. These collaborations have enriched his research and contributed to the development of innovative solutions for retinal health.
Conclusion
Thierry Léveillard's contributions to retinal health through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in the diagnosis and treatment of retinal diseases.